BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

Data suggesting an inhaled IFNB1 product from Synairgen can reduce the chance a patient with COVID-19 develops severe disease gave a jolt to the biotech’s shares Monday, but more statistically robust data are still needed...
BioCentury | Jul 18, 2020
Product Development

COVID-19 mAb developers weigh master protocols as they set clinical strategies

Drugmakers developing the first crop of COVID-specific mAbs are facing the question of whether to pursue independent, company-sponsored trials or participate in master protocols that have been successful for repurposed drugs during the pandemic. So...
BioCentury | Jun 30, 2020
Product Development

The U.K.’s push for COVID-19 master protocols pays off again with definitive data on lopinavir-ritonavir

The U.K.’s RECOVERY trial and broader strategy to encourage master protocol participation are proving their value again, this time with data showing that the lopinavir-ritonavir antiviral cocktail has no clinical benefit in hospitalized patients not...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Jun 6, 2020
Product Development

Over 200 COVID-19 trials nearing completion should provide a busy summer of data readouts

Less than three months after COVID-19 reached pandemic status, and five since the virus was sequenced, drug development has reached the point where hundreds of clinical trials will soon read out. With a pile of...
BioCentury | May 9, 2020
Product Development

REMAP-CAP master protocol has lessons for studying drug cocktails

The U.K.’s REMAP-CAP master protocol is poised to teach drug developers a way to cut through the mess of individual trials for drug combos in diseases where drug cocktails are all but inevitable. If successful,...
BioCentury | Apr 21, 2020
Product Development

After pledging to donate millions of hydroxychloroquine doses, Novartis readies trial to assess drug’s benefit for COVID-19

A month after committing to donate up to 130 million doses of hydroxychloroquine for COVID-19 trials, Novartis is starting its own trial to find out if the malaria drug actually works in patients infected with...
BioCentury | Apr 15, 2020
Politics, Policy & Law

WHO names former GSK CEO Witty to co-lead COVID-19 vaccine after Trump cuts U.S. funding

Andrew Witty will take a leave of absence from his roles as president of UnitedHealth and CEO of the group’s Optum health services unit to co-lead WHO’s program to accelerate the development of COVID-19 vaccines....
BioCentury | Apr 15, 2020
Product Development

AZ targeting cytokine storms as ranks of repurposed agents for COVID-19 grow

AstraZeneca joins the growing list of companies targeting cytokine storms caused by COVID-19 with plans to start a trial of its Btk inhibitor to treat patients with severe disease. The announcement came Tuesday amid another...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with countermeasures beyond physical...
Items per page:
1 - 10 of 588